Skip to main content
Premium Trial:

Request an Annual Quote

HD Biosciences, Luxcel Ink Marketing Deal for Mitochondria Assays

NEW YORK (GenomeWeb) – Chinese contract research organization HD Biosciences (HDB) has signed an agreement to co-market and sell Luxcel Biosciences' mitochondria assays and technologies for preclinical drug safety testing, the companies announced today.

Luxcel offers a range of phosphorescence- and fluorescence-based sensors and tests including assays for mitochondrial function, metabolism, and toxicity. Under the terms of the deal, HDB will have access to these assays and technologies, including Luxcel's respirometric screening technology assay for differentiating specific mitochondrial toxicity from non‐specific toxicity, and un-couplers of mitochondrial function from inhibitors.

Additional terms were not disclosed.

"HDB offers a full range of in vitro toxicology services including safety profiling panels, as well as cardiotoxicity, hepatotoxicity, genotoxicity, and cytotoxicity screenings," Peiyuan Lin, senior vice president of research and development at HDB, said in a statement. "Luxcel's growing portfolio of proprietary mitochondria toxicity, bioenergetics, and metabolism assays is highly complementary to our current offerings and provides early and effective identification of mitochondrial liabilities for our clients' drug-discovery programs."

WuXi Apptec acquired HDB earlier this year.